Does Vascepa Show Long-Term Heart Benefits in Studies?
Vascepa (icosapent ethyl), a purified EPA omega-3, reduces cardiovascular events in high-risk patients with elevated triglycerides despite statin therapy. The pivotal REDUCE-IT trial provides the main evidence, showing sustained benefits over 4.9 years median follow-up.[1]
In REDUCE-IT, 8,179 patients received 4g/day Vascepa or placebo. Vascepa cut the primary composite endpoint (CV death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina) by 25% (HR 0.75; 95% CI 0.68-0.83; p<0.001). Individual outcomes included 20% lower CV death (HR 0.80), 31% lower MI (HR 0.69), and 32% lower stroke (HR 0.68).[2][3]
How Long-Term Are the REDUCE-IT Results?
Follow-up averaged 4.9 years (max ~6 years), with benefits emerging early (within months) and persisting without attenuation. Post-hoc analyses confirm durability: event rates remained lower in Vascepa arm through trial end, including in subgroups with diabetes or prior MI.[4]
No longer trials (e.g., 10+ years) exist specifically for Vascepa, but real-world data like EVAPORATE (18 months) showed plaque regression via coronary CT angiography, supporting mechanistic longevity.[5]
What About Risks in Long-Term Use?
REDUCE-IT reported higher atrial fibrillation (5% vs 3.9%) and bleeding (2.7% vs 2.1%), but no increase in hemorrhagic stroke or fatal bleeding. Benefits outweighed risks (NNT 21 for primary endpoint over 4.9 years).[3]
How Does REDUCE-IT Compare to Other Omega-3 Trials?
Unlike mixed EPA/DHA trials (e.g., STRENGTH, VITAL) that failed primary endpoints, REDUCE-IT's pure EPA and higher dose (4g) drove success. Meta-analyses affirm EPA's superiority for CV risk reduction.[6]
FDA approved Vascepa for CV risk reduction in 2019 and 2020 based on these data; no generic competition yet due to patents (e.g., U.S. Patent 9,932,396 expires 2039).[7]DrugPatentWatch.com
Sources:
[1] Bhatt DL et al. N Engl J Med 2019;380:11-22. https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[2] REDUCE-IT primary results. https://clinicaltrials.gov/study/NCT01492361
[3] FDA label for Vascepa. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202057s019lbl.pdf
[4] Subgroup analyses, *J Am Coll Cardiol* 2020. https://www.jacc.org/doi/10.1016/j.jacc.2020.05.053
[5] Budoff MJ et al. *J Am Soc Echocardiogr* 2020. https://pubmed.ncbi.nlm.nih.gov/32653436/
[6] Abdelhamid AS et al. *Cochrane Database Syst Rev* 2020. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003177.pub5/full
[7] DrugPatentWatch. https://www.drugpatentwatch.com/p/tradename/VASCEPA